EGFR-IN-196 

EGFR-IN-196 is an EGFR inhibitor with an IC₅₀ of 105.96 nM. EGFR-IN-196 inhibits EGFR enzymatic activity, reduces phosphorylated PI3K levels, and suppresses downstream EGFR-AKT signaling. EGFR-IN-196 increases intracellular ROS generation, induces mitochondrial depolarisation, and induces apoptosis in cancer cells. EGFR-IN-196 can be used for the research of lung cancer^[1].

EGFR-IN-196 (Compound 6E) inhibits purified EGFR kinase with an IC₅₀ of 105.96 ± 0.45 nM^[1].
EGFR-IN-196 (1-25 μM; 24 h) inhibits A549 lung cancer cell proliferation with an IC₅₀ of 4.355 ± 0.028 μM and is non-toxic to HEK293 normal cells at 25 μM for 24 h^[1].
EGFR-IN-196 (5-30 min) time-dependently reduces phosphorylated PI3K levels in viable A549 lung cancer cells, inhibiting downstream EGFR signaling^[1].
EGFR-IN-196 (4.355 μM; 24 h) increases intracellular ROS levels and disrupts mitochondrial membrane potential in A549 lung cancer cells^[1].
EGFR-IN-196 (4.355 μM; 24 h) induces apoptosis in A549 lung cancer cells, with 19.6% early and 13.1% late apoptotic cells observed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351.31

C₁₈H₁₁F₂N₅O

O=C(N)C1=NC(C2=CC=C(F)C=C2)=NC3=C1N=CN3C4=CC=C(F)C=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chatterjee J, et al. Design, catalyst-free synthesis, DFT study and anticancer assessment of new 2,9-disubstituted purine-6-carboxamides. Bioorg Chem. 2026 May;172:109529.  [Content Brief]